nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.06.2007 | Original Paper

Clinical significance of aromatase protein expression in axillary node negative breast cancer

verfasst von: Jingsong Lu, Hecheng Li, Daocheng Cao, Genhong Di, Jiong Wu, Kunwei Sheng, Qixia Han, Zhenzhou Shen, Zhiming Shao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Aromatase catalyzes the conversion of androgens to estrogens; its high expression in breast cancers may be responsible for the local high levels of estrogen and may promote tumor growth and progression; however, the clinical importance of aromatase remains unclear and needs to be further researched.

Methods

By immunochemistry, we detected aromatase, MMP2 and MMP9 immunoreactivity in 244 axillary lymph node negative breast cancers.

Results

Aromatase immunoreactivity was positively associated with co-expression of MMP2 and MMP9 (MMP2/9) in the estrogen receptor and/or progestin receptor- (ER/PR) positive patients (P < 0.05), but not in the ER and PR negative patients (P > 0.05); aromatase status positively associated with tumor size in the postmenopausal patients (P < 0.05) but not in the premenopausal patients (P > 0.05). The proportional hazards assumption was violated for aromatase status (global test, P < 0.05), and aromatase was an unfavorable prognostic factor for disease-free survival (DFS) (P = 0.04) in multivariate analysis of time-dependent non-proportional Cox regression. In the ER/PR-positive patients, positive aromatase staining was significantly associated with decreased overall survival (OS) (P = 0.04), but there was no such association in the ER and PR negative patients (P > 0.05).

Conclusions

Our study suggested that local estrogen production by aromatase plays important roles in the growth and invasiveness of breast cancer; tumor aromatase status may be indicative of breast cancer prognosis in some patients.

Abbas Abidi SM, Howard EW, Dmytryk JJ, Pento JT (1997) Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis 15:432–439PubMedCrossRef

Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz A, Llopis F, Garcia-Conde J, Romero R (1992) Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 10:438–446PubMed

Brodie A, Long B, Lu Q (1998) Aromatase expression in the human breast. Breast Cancer Res Treat 49(Suppl 1):S85–S91, discussion S109–S119

Brodie A, Lu Q, Long B (1999) Aromatase and its inhibitors. J Steroid Biochem Mol Biol 69:205–210PubMedCrossRef

Brodie A, Lu Q, Nakamura J (1997) Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol 61:281–286PubMed

Brodie AH, Mouridsen HT (2003) Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. Am J Clin Oncol 26:S17–S26PubMedCrossRef

Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH (2001) Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79:41–47PubMedCrossRef

Buzdar AU (2003) Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 8:335–341PubMedCrossRef

Dowsett M, Detre S, Rowlands M, Grimshaw R (1996) Oestrogen formation in breast: clinical and biological importance. J Endocrinol 150:S59–S63PubMed

Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2:252–257PubMedCrossRef

Ellis MJ, Hayes DF, Lippman ME (2004) Treatment of metastastatic breast cancer In: Harris Jr, Lippmen Me, Morrow M, Osborne Ck (eds) Disease of the breast. Lippincott Williams & Wilkins, Philadephia, pp 1101–1159

Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathology 1991; 19:403–410. Histopathology 41:151

Eppenberger U, Levano S, Schoumacher F, Muller H, Eppenberger-Castori S (2001) Molecular epidemiology of aromatase expression in 1182 primary breast cancers. In: Miller W, Santen R (eds) Aromatase inhibition and breast cancer. Marcel Dekker, New York, pp 199–212

Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE, Chen S (1992) Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 140:337–343PubMed

Evans TR, Rowlands MG, Silva MC, Law M, Coombes RC (1993) Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J Steroid Biochem Mol Biol 44:583–587PubMedCrossRef

Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292–1299PubMedCrossRef

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227–237PubMedCrossRef

Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) in T(1-2) no breast carcinoma. Breast Cancer Res Treat 77:85–91PubMedCrossRef

Hsu SM, Raine L, Fanger H (1981) Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580PubMed

Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y (1996) Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 87:602–611PubMed

Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218–1226PubMed

Kinoshita Y, Chen S (2003) Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Cancer Res 63:3546–3555PubMed

Kirma N, Gill K, Mandava U, Tekmal RR (2001) Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Res 61:1910–1918PubMed

Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y (2000) Gelatinolytic activity of matrix metalloproteinase-2 and–9 in oesophageal carcinoma; a study using in situ zymography. Eur J Cancer 36:2164–2170PubMedCrossRef

Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD (1992) Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52:5198–5203PubMed

Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G, Brodie A (1996) Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137:3061–3068PubMedCrossRef

Mandava U, Kirma N, Tekmal RR (2001) Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology. J Steroid Biochem Mol Biol 79:27–34PubMedCrossRef

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856–1865PubMedCrossRef

Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP, Karamanos NK (2003) Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 104:155–160PubMedCrossRef

Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y, Noguchi S (2003) High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 9:2288–2293PubMed

Pacheco MM, Nishimoto IN, Mourao Neto M, Mantovani EB, Brentani MM (2001) Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis. Int J Biol Markers 16:62–68PubMed

Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre–and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81:1460–1464PubMedCrossRef

Pasqualini JR, Chetrite GS (2005) Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 93:221–236PubMedCrossRef

Sasano H, Suzuki T, Moriya T (2001) Immunohistochemistry of aromatase: a recent new development. In: Miller W, Santen R (eds) Aromatase inhibition and breast cancer. Marcel Dekker, New York, pp 191–198

Shenton KC, Dowsett M, Lu Q, Brodie A, Sasano H, Sacks NP, Rowlands MG (1998) Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas. Breast Cancer Res Treat 49(Suppl 1):S101–S107, discussion S109–S119

Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I, Coombes RC (1989) Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 49:2588–2591PubMed

Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T (1998) Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83:1153–1162PubMedCrossRef

Tekmal RR, Ramachandra N, Gubba S, Durgam VR, Mantione J, Toda K, Shizuta Y, Dillehay DL (1996) Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 56:3180–3185PubMed

Turner KJ, Macpherson S, Millar MR, McNeilly AS, Williams K, Cranfield M, Groome NP, Sharpe RM, Fraser HM, Saunders PT (2002) Development and validation of a new monoclonal antibody to mammalian aromatase. J Endocrinol 172:21–30PubMedCrossRef

van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45:2900–2906PubMed

Wolczynski S, Surazynski A, Swiatecka J, Palka J (2001) Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecol Endocrinol 15:225–233PubMed

Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S (1996) Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59:163–171PubMedCrossRef

Titel: Clinical significance of aromatase protein expression in axillary node negative breast cancer
verfasst von: Jingsong Lu
Hecheng Li
Daocheng Cao
Genhong Di
Jiong Wu
Kunwei Sheng
Qixia Han
Zhenzhou Shen
Zhiming Shao
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 6/2007
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-006-0186-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Clinical significance of aromatase protein expression in axillary node negative breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells

A glycoproteome database of normal human liver tissue

A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer

Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells

Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations

MYH mutations are rare in prostate cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie